Erika F. Werner

Erika F. Werner

Auto-generated profile, based on publicly available information

Erika F. Werner

Department of Obstetrics and Gynecology, Women & Infants Hospital of Rhode Island, Warren Alpert Medical School, Brown University, Providence, Rhode Island

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2015 in Environmental Health
Verified
Journal Article
Open access
PDF file
EWErika F. Werner
Erika F. Werner
JBJoseph M. Braun
Joseph M. Braun
KYKimberly Yolton
Kimberly Yolton
JKJane C. Khoury
Jane C. Khoury
BLBruce P. Lanphear
Bruce P. Lanphear
Exposure to phthalates, a class of endocrine disrupting chemicals, is ubiquitous. We examined the association of urinary phthalate metabolite concentrations during pregnancy with maternal blood pressure and risk of pregnancy-induced hypertensive diseases. We used data from the Health Outcomes and Measures of the Environment Study, a prospective birth cohort of low-risk pregnant women recruited between March 2003 and January 2006. We analyzed maternal urine samples collected at 16 and 26 weeks gestation for 9 phthalate monoester metabolites reflecting exposure to 6 phthalate diesters. Outcomes included maternal blood pressure at <20 and ≥20 weeks gestation and pregnancy induced hypertensive diseases (gestational hypertension, preeclampsia, eclampsia, and HELLP syndrome). Data were available for 369 women who gave birth to singleton, live-born infants without congenital anomalies. Of the phthalate metabolites evaluated, only mono-benzyl phthalate (MBzP) concentrations were significantly associated with maternal diastolic blood pressure at <20 weeks gestation. Women in the third MBzP tercile at 16 weeks gestation had diastolic blood pressure 2.2 (95 % CI: 0.5–3.9) mm Hg higher at <20 weeks gestation and 2.8 (95 % CI: 0.9–4.7) mm Hg higher at ≥20 weeks gestation compared to women in the first tercile. Compared to women in the first tercile, women in the top MBzP tercile at 16 weeks had an increased risk of developing pregnancy-induced hypertensive diseases (RR = 2.92, 95 % CI 1.15–7.41, p-value for trend = 0.01). MBzP concentrations at 26 weeks gestation were not as strongly associated with blood pressure at ≥20 weeks gestation or risk of pregnancy-induced hypertensive diseases. This study suggests that maternal urinary MBzP concentrations may be associated with increased diastolic blood pressure and risk of pregnancy-induced hypertensive diseases.

1 September 2020 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
EWErika F. Werner
Erika F. Werner
PHPhinnara Has
Phinnara Has
DRDwight Rouse
Dwight Rouse
MCMelissa A. Clark
Melissa A. Clark

11 September 2020 in Environmental Health
Verified
Journal Article
Open access
PDF file
KCKathryn A. Crawford
Kathryn A. Crawford
NHNicola Hawley
Nicola Hawley
ACAntonia M. Calafat
Antonia M. Calafat
NJNayana K. Jayatilaka
Nayana K. Jayatilaka
RFRosemary J. Froehlich
Rosemary J. Froehlich
Megan RomanoMegan Romano
Megan Romano
Background: Organophosphate esters (OPEs)—used as flame retardants and plasticizers—are associated with adverse pregnancy outcomes such as reduced fecundity and live births and increased preterm delivery. OPEs may interfere with growth and metabolism via endocrine-disruption, but few studies have investigated endocrine-related outcomes. The objective of this pilot study (n = 56 mother-infant pairs) was to evaluate associations of OPEs with gestational weight gain (GWG), gestational age at delivery, infant anthropometry, and infant feeding behaviors.Methods: We quantified OPE metabolites (bis-2-chloroethyl phosphate [BCEP], bis (1,3-dichloro-2-propyl) phosphate [BDCPP], diphenyl phosphate [DPHP]) in pooled maternal spot urine collected throughout pregnancy (~ 12, 28, and 35 weeks’ gestation). We obtained maternal sociodemographic characteristics from questionnaires administered at enrollment and perinatal characteristics from medical record abstraction. Trained research assistants measured infant weight, length, head and abdominal circumferences, and skinfold thicknesses at birth and 6 weeks postpartum. Mothers reported infant feeding behavior via the Baby Eating Behavior Questionnaire (BEBQ). Using multiple linear regression, we assessed associations of log2-transformed maternal urinary OPE metabolites with GWG, gestational age at delivery, infant anthropometry at birth, weekly growth rate, and BEBQ scores at 6 weeks postpartum. We used linear mixed effects (LME) models to analyze overall infant anthropometry during the first 6 weeks of life. Additionally, we considered effect modification by infant sex.Results: We observed weak positive associations between all OPE metabolites and GWG. In LME models, BDCPP was associated with increased infant length (β = 0.44 cm, 95%CI = 0.01, 0.87) and weight in males (β = 0.14 kg, 95%CI = 0.03, 0.24). BDCPP was also associated with increased food responsiveness (β = 0.23, 95%CI = 0.06, 0.40). DPHP was inversely associated with infant abdominal circumference (β = − 0.50 cm, 95%CI = − 0.86, − 0.14) and female weight (β = − 0.19 kg, 95%CI = − 0.36, − 0.02), but positively associated with weekly growth in iliac skinfold thickness (β = 0.10 mm/wk., 95%CI = 0.02, 0.19). Further, DPHP was weakly associated with increased feeding speed. BCEP was associated with greater infant thigh skinfold thickness (β = 0.34 mm, 95%CI = 0.16, 0.52) and subscapular skinfold thickness in males (β = 0.14 mm, 95%CI = 0.002, 0.28).Conclusions: Collectively, these findings suggest that select OPEs may affect infant anthropometry and feeding behavior, with the most compelling evidence for BDCPP and DPHP.

30 July 2018 in American Journal of Perinatology
Verified
Journal Article
Closed access
PDF file
PHPhinnara Has
Phinnara Has
LKLindsey Kanno
Lindsey Kanno
ASAdam Sullivan
Adam Sullivan
MCMelissa A. Clark
Melissa A. Clark
EWErika F. Werner
Erika F. Werner
Objective To identify barriers to postpartum glucose testing in women with a history of gestational diabetes mellitus (GDM). Materials and Methods This is a prospective cohort study of 300 women with GDM who completed questionnaires on socioeconomic barriers and validated instruments to measure trust in their clinician and health agency. At 12 weeks' postpartum, women were recontacted and postpartum records were collected. Women who completed glucose testing between 4 and 12 weeks' postpartum were compared with women who did not with regard to modifiable and nonmodifiable barriers to care. Results Of the 373 women approached, 300 (80%) consented to participate, completed surveys on postpartum day 2, and had records retrieved at 12 weeks' postpartum. Validated instruments used showed internal consistency (Cronbach's α > 0.6). Only 126 (42%) of the participants completed postpartum glucose testing, and these women were more likely to have reliable transportation, private insurance, college degrees, and higher annual household incomes (p < 0.05). Postpartum glucose testing was also associated with trust in clinicians (p = 0.01) but not health agency (p = 0.66). The association between trust and postpartum glucose testing persisted after adjusting for nonmodifiable barriers. Conclusion Maximizing trust in clinicians should be a focus of prenatal GDM care to maximize the likelihood of postpartum glucose testing.

1 April 2020 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
EWErika F. Werner
Erika F. Werner
LSLauren E. Schlichting
Lauren E. Schlichting
WGWilliam A. Grobman
William A. Grobman
SVSamara Viner-Brown
Samara Viner-Brown
MCMelissa Clark
Melissa Clark
PVPatrick M. Vivier
Patrick M. Vivier
In August 2018, the results of the ARRIVE trial were published.1 In this multicenter trial, low-risk, nulliparous women were randomized to either undergo labor induction or expectant management at 39 weeks of gestation. The study demonstrated a reduced risk of cesarean delivery (18.6% vs 22.2%; relative risk [RR], 0.84; 95% CI, 0.76-0.93) and hypertensive disorders of pregnancy (9.1% vs 14.1%; RR, 0.64; 95% CI, 0.56-0.74) in the group of women assigned to induction compared with those assigned to expectant management.1 Furthermore, induction at 39 weeks of gestation compared with expectant management past 39 weeks was not associated with an increased risk of any neonatal complication. The results of this trial have led many clinicians to begin offering elective induction to low-risk nulliparous women at 39 weeks.

28 July 2020 in American Journal of Perinatology
Verified
Journal Article
Closed access
PDF file
KGKimberly B. Glazer
Kimberly B. Glazer
VDValery A. Danilack
Valery A. Danilack
AFAlison E. Field
Alison E. Field
EWErika F. Werner
Erika F. Werner
DSDavid A. Savitz
David A. Savitz
Objective Findings of the recent ARRIVE (A Randomized Trial of Induction Versus Expectant Management) trial, showing reduced cesarean risk with elective labor induction among low-risk nulliparous women at 39 weeks' gestation, have the potential to change interventional delivery practices but require examination in wider populations. The aim of this study was to identify whether term induction of labor was associated with reduced cesarean delivery risk among women with obesity, evaluating several maternal characteristics associated with obesity, induction, and cesarean risk. Study Design We studied administrative records for 66,280 singleton, term births to women with a body mass index ≥30, without a prior cesarean delivery, in New York City from 2008 to 2013. We examined elective inductions in 39 and 40 weeks' gestation and calculated adjusted risk ratios for cesarean delivery risk, stratified by parity and maternal age. We additionally evaluated medically indicated inductions at 37 to 40 weeks among women with obesity and diabetic or hypertensive disorders, comorbidities that are strongly associated with obesity. Results Elective induction of labor was associated with a 25% (95% confidence interval: 19–30%) lower adjusted risk of cesarean delivery as compared with expectant management at 39 weeks of gestation and no change in risk at 40 weeks. Patterns were similar when stratified by parity and maternal age. Risk reductions in week 39 were largest among women with a prior vaginal delivery. Women with comorbidities had reduced cesarean risk with early term induction and in 39 weeks. Conclusion Labor induction at 39 weeks was consistently associated with reduced risk of cesarean delivery among women with obesity regardless of parity, age, or comorbidity status. Cesarean delivery findings from induction trials at 39 weeks among low-risk nulliparous women may generalize more broadly across the U.S. obstetric population, with potentially larger benefit among women with a prior vaginal delivery. Key Points